Exhibit 99.1 Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates CAMBRIDGE, Mass., August 12, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2025 and provided a business update. Research and Development (R&D) Expenses: R&D expenses were $21. ...